About

PharmaEssentia is working to redefine the potential of proven therapies to enhance the health and quality of life for patients living with hematologic diseases. Powered by world-class expertise and grounded in pioneering science, we are developing novel treatment solutions, beginning with therapies for myeloproliferative neoplasms (MPNs). Our flagship product, BESREMi, was approved by FDA in 2021 for all-comers polycythemia vera. About PharmaEssentia Corp. PharmaEssentia is working to redefine the potential of proven therapies to enhance the health and quality of life for patients living with hematologic diseases. Powered by world-class expertise and grounded in pioneering science, we are developing novel treatment solutions, beginning with therapies for myeloproliferative neoplasms (MPNs). We’re working to develop new hematology/oncology therapies by looking at a proven therapeutic concept with a fresh perspective. Drawing on our deep biopharmaceutical expertise, we’re aiming to transform the risk/benefit profiles of existing therapies. Our goal: to give physicians new therapeutic tools for early intervention—while giving new hope to patients with rare cancers. About PharmaEssentia Corp PharmaEssentia is working to redefine the potential of proven therapies to enhance the health and quality of life for patients living with hematologic diseases. Powered by world-class expertise and grounded in pioneering science, we are developing novel treatment solutions, beginning with therapies for myeloproliferative neoplasms (MPNs). We’re working to develop new hematology/oncology therapies by looking at a proven therapeutic concept with a fresh perspective. Drawing on our deep biopharmaceutical expertise, we’re aiming to transform the risk/benefit profiles of existing therapies. Our goal: to give physicians new therapeutic tools for early intervention—while giving new hope to patients with rare cancers. PharmaEssentia Corporation (TWSE: 6446) headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. PharmaEssentia Crop., headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator and the developer and owner of BESREMi® (ropeginterferon alfa-2b-njft). Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.